基于荟萃分析和癌症基因组图谱（TCGA）数据集评估微小RNA-203在实体瘤中的预后价值。

Evaluating the Prognostic Value of microRNA-203 in Solid Tumors Based on a Meta-Analysis and the Cancer Genome Atlas (TCGA) Datasets.

作者信息

Shao Yingjie, Gu Wendong, Ning Zhonghua, Song Xing, Pei Honglei, Jiang Jingting

机构信息

Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.

Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.

出版信息

Cell Physiol Biochem. 2017;41(4):1468-1480. doi: 10.1159/000470649. Epub 2017 Mar 24.

DOI:10.1159/000470649

PMID:28351024

Abstract

BACKGROUND

It has been reported that miR-203 expression was aberrant in various types of cancers, and it could be used as a prognostic biomarker. Therefore, in this study, we aimed to evaluate the prognostic value of miR-203 expression in solid tumors by using meta-analysis and The Cancer Genome Atlas (TCGA) datasets.

METHODS

By doing a literature research in PubMed, Embase and the Cochrane Library (last update by December 2016), we were able to identify the studies assessing the prognostic role of miR-203 in various tumors. We then used TCGA datasets to validate the results of meta-analysis.

RESULTS

33 studies from 26 articles were qualified and enrolled in this meta-analysis. Pooled analyses showed that higher expression of miR-203 in tissues couldn't predict poor overall survival (OS) and progression-free survival (PFS) in solid tumors. However, the results of subgroup analyses revealed that the upregulation of tissue miR-203 expression was associated with poor OS in colorectal cancer (hazard ratio (HR)=1.81, 95% confidence intervals (CI) 1.31-2.49; P<0.001), pancreatic cancer (HR=1.19, 95% CI 1.09-1.31; P<0.001) and ovarian cancer (HR=1.85, 95% CI 1.45-2.37; P<0.001); but it had opposite association in liver cancer (HR=0.52, 95% CI 0.28-0.97; P=0.040) and esophageal cancer (HR=0.41, 95% CI 0.25-0.66; P<0.001). Based on TCGA datasets, we found the same results for pancreatic cancer and esophageal cancer, but not for colorectal cancer and liver cancer. Moreover, patients with high circulating miR-203 in blood had significantly poor OS and PFS in colorectal cancer and breast cancer.

CONCLUSION

Our study showed that the prognostic values of tissue miR-203 varied in different tumor types. In addition, the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer.

摘要

背景

据报道，miR-203在多种癌症类型中表达异常，且可作为一种预后生物标志物。因此，在本研究中，我们旨在通过荟萃分析和癌症基因组图谱（TCGA）数据集评估miR-203表达在实体瘤中的预后价值。

方法

通过在PubMed、Embase和Cochrane图书馆（截至2016年12月的最新更新）进行文献研究，我们得以识别评估miR-203在各种肿瘤中预后作用的研究。然后我们使用TCGA数据集来验证荟萃分析的结果。

结果

来自26篇文章的33项研究符合条件并纳入本荟萃分析。汇总分析表明，组织中miR-203的高表达不能预测实体瘤的总生存期（OS）和无进展生存期（PFS）不佳。然而，亚组分析结果显示，组织miR-203表达上调与结直肠癌（风险比（HR）=1.81，95%置信区间（CI）1.31-2.49；P<0.001）、胰腺癌（HR=1.19，95%CI 1.09-1.31；P<0.001）和卵巢癌（HR=1.85，95%CI 到1.45-2.37；P<0.001）的OS不佳相关；但在肝癌（HR=0.52，95%CI 0.28-0.97；P=0.040）和食管癌（HR=0.41，95%CI 0.25-0.66；P<0.001）中则呈相反关联。基于TCGA数据集，我们在胰腺癌和食管癌中发现了相同结果，但在结直肠癌和肝癌中未发现。此外，血液中循环miR-203水平高的结直肠癌和乳腺癌患者的OS和PFS明显较差。